Published in Curr Opin Neurol on December 01, 2003
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.11
Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats. Psychopharmacology (Berl) (2008) 1.06
Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol (2006) 1.01
Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol (2015) 0.97
Oxidative stress and microglial cells in Parkinson's disease. Mediators Inflamm (2012) 0.96
The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology (Berl) (2008) 0.95
Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behav Brain Res (2009) 0.95
Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience (2010) 0.91
Cabergoline associated with first episode mania. Psychosomatics (2012) 0.91
Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol (2010) 0.88
Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice. Neuroscience (2013) 0.83
Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion. Neurobiol Dis (2011) 0.83
Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor. J Biol Chem (2014) 0.82
TMS-assisted neurophysiological profiling of the dopamine receptor agonist cabergoline in human motor cortex. J Neural Transm (Vienna) (2006) 0.81
Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. Eur Neuropsychopharmacol (2008) 0.81
Cell therapies for Parkinson's disease: how far have we come? Regen Med (2016) 0.79
A two-step target binding and selectivity support vector machines approach for virtual screening of dopamine receptor subtype-selective ligands. PLoS One (2012) 0.79
Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders. PLoS One (2014) 0.78
Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease. Curr Neuropharmacol (2016) 0.78
Neural grafting for Parkinson's disease: challenges and prospects. Neural Regen Res (2017) 0.75
Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents. P T (2015) 0.75
Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question. Mol Neurobiol (2016) 0.75
Levodopa therapy from the neuroprotection viewpoint. From a clinical outlook. J Neurol (2005) 0.75